![]() Recently, we reported a significant correlation between intercellular adhesion molecule (ICAM)-1 expression and the malignant features of thyroid cancer 5, including BRAF point mutations (V600E) 6. ![]() Due to the scarcity of targetable antigens in the solid tumor setting and concerns of off-tumor reactions of immune cells with healthy tissues, the successful application of CAR T cells to solid cancers has been limited 4. These studies support the initiation of a phase I study to evaluate the safety and potential efficacy of micromolar affinity tuned CAR T cells against newly diagnosed anaplastic and refractory or recurrent thyroid cancers.Īdoptive cellular therapy using chimeric antigen receptor (CAR) T cells has benefited from significant technological advancements and lead to impressive clinical outcomes in selected hematological malignancies 1, 2, 3. Selective anti-tumor activity in the absence of toxicity provides proof-of-concept that micromolar affinity tuned CAR T cells can be used to target tumors expressing high levels of antigen while avoiding normal tissues expressing basal levels of the same antigen. We examined cross-reactivity of CAR T cells toward both human and murine ICAM-1 and ICAM-1 expression in human and mouse tissues to demonstrate that both efficacy and on-target, off-tumor toxicity can be studied in our preclinical model. The resulting CAR T cells were formulated for cryopreservation to be used directly for infusion into patients after thawing with no further processing. Using Prodigy, thawed leukopak cells were enriched for CD4 + and CD8 + T cells, subjected to double transduction using lentiviral vector, and expanded in culture for a total of 10 days with a final yield of 2–4 × 10 9 cells. Herein, we report the automated process of CAR T cell manufacturing with CliniMACS Prodigy (Miltenyi Biotec) using cryopreserved peripheral blood leukocytes from apheresis collections. For clinical translation of this novel modality, we designed CAR T cells possessing micromolar rather than nanomolar affinity to ICAM-1 to avoid cytotoxicity in normal cells with basal levels of ICAM-1 expression. ![]() Previously, we have shown a significant correlation between ICAM-1 overexpression and malignancy in thyroid cancer, and have pioneered the use of ICAM-1 targeted CAR T cells as a novel treatment modality. While the majority of thyroid cancer patients are easily treatable, those with anaplastic or poorly differentiated recurrent thyroid carcinomas have a very poor prognosis with a median survival of less than a year.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |